146 related articles for article (PubMed ID: 1558794)
1. Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.
Richard B; Launay-Iliadis MC; Iliadis A; Just-Landi S; Blaise D; Stoppa AM; Viens P; Gaspard MH; Maraninchi D; Cano JP
Br J Cancer; 1992 Mar; 65(3):399-404. PubMed ID: 1558794
[TBL] [Abstract][Full Text] [Related]
2. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.
Mulder PO; Sleijfer DT; Willemse PH; de Vries EG; Uges DR; Mulder NH
Cancer Res; 1989 Aug; 49(16):4654-8. PubMed ID: 2545349
[TBL] [Abstract][Full Text] [Related]
3. Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
Canal P; Attal M; Chatelut E; Guichard S; Huguet F; Muller C; Schlaifer D; Laurent G; Houin G; Bugat R
Cancer Res; 1993 Oct; 53(20):4850-4. PubMed ID: 8402672
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of mitoxantrone performed by a NONMEM method.
Launay MC; Iliadis A; Richard B
J Pharm Sci; 1989 Oct; 78(10):877-80. PubMed ID: 2600798
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and metabolism of mitoxantrone. A review.
Ehninger G; Schuler U; Proksch B; Zeller KP; Blanz J
Clin Pharmacokinet; 1990 May; 18(5):365-80. PubMed ID: 2185907
[TBL] [Abstract][Full Text] [Related]
7. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
Schleyer E; Kamischke A; Kaufmann CC; Unterhalt M; Hiddemann W
Leukemia; 1994 Mar; 8(3):435-40. PubMed ID: 8127148
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma.
Stiff PJ; McKenzie RS; Alberts DS; Sosman JA; Dolan JR; Rad N; McCloskey T
J Clin Oncol; 1994 Jan; 12(1):176-83. PubMed ID: 8270975
[TBL] [Abstract][Full Text] [Related]
9. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
[TBL] [Abstract][Full Text] [Related]
10. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Attal M; Canal P; Schlaifer D; Chatelut E; Dezeuze A; Huguet F; Payen C; Pris J; Laurent G
J Clin Oncol; 1994 Jan; 12(1):141-8. PubMed ID: 8270970
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
12. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation.
Rodman JH; Murry DJ; Madden T; Santana VM
J Clin Oncol; 1994 Nov; 12(11):2390-7. PubMed ID: 7964955
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma.
Hu OY; Chang SP; Law CK; Jian JM; Chen KY
Cancer; 1992 Feb; 69(4):847-53. PubMed ID: 1735075
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy.
Van Belle SJ; de Planque MM; Smith IE; van Oosterom AT; Schoemaker TJ; Deneve W; McVie JG
Cancer Chemother Pharmacol; 1986; 18(1):27-32. PubMed ID: 3757156
[TBL] [Abstract][Full Text] [Related]
15. Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas.
Tranchand B; Lucas C; Biron P; Giroux B; Gordon B; Richards R; Solere P; Roux N; Evene E; Mornex F
Cancer Chemother Pharmacol; 1993; 32(1):46-52. PubMed ID: 8462123
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of high dose thiotepa in children undergoing autologous bone marrow transplantation.
Kletzel M; Kearns GL; Wells TG; Thompson HC
Bone Marrow Transplant; 1992 Aug; 10(2):171-5. PubMed ID: 1525606
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer.
Marchbanks K; Dudley MN; Posner MR; Darnowski J
Pharmacotherapy; 1995; 15(4):451-7. PubMed ID: 7479197
[TBL] [Abstract][Full Text] [Related]
18. Disposition of mitoxantrone in cancer patients.
Alberts DS; Peng YM; Leigh S; Davis TP; Woodward DL
Cancer Res; 1985 Apr; 45(4):1879-84. PubMed ID: 3978648
[TBL] [Abstract][Full Text] [Related]
19. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone.
Greidanus J; de Vries EG; Mulder NH; Sleijfer DT; Uges DR; Oosterhuis B; Willemse PH
J Clin Oncol; 1989 Jun; 7(6):790-7. PubMed ID: 2715807
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics and metabolism of mitoxantrone in man.
Ehninger G; Proksch B; Heinzel G; Schiller E; Weible KH; Woodward DL
Invest New Drugs; 1985; 3(2):109-16. PubMed ID: 4019115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
